Interpace Biosciences — Third Quarter 2026 Earnings Summary
Financial Performance:
- Q3 2026 revenue was $10.4 million, an 18% year-over-year increase from $8.8 million in Q3 2025.
- Nine-month 2026 revenue was $28.5 million, a decrease from $29.5 million in the prior year period, but a 13% increase on a Pro Forma basis compared to $25.3 million.
- Q3 2026 gross profit margin was 69%, up from 62% in Q3 2025 and 63% on a Pro Forma basis.
- Nine-month 2026 gross profit margin was 66%, up from 61% in the prior year period and 59% on a Pro Forma basis.
- Q3 2026 Adjusted EBITDA was $2.1 million (20% margin), compared to $1.3 million (14% margin) in Q3 2025.
- Nine-month 2026 Adjusted EBITDA was $4.4 million (15% margin), compared to $3.7 million (13% margin) in the prior year period and $2.5 million (10% margin) on a Pro Forma basis.
- Q3 2026 loss from continuing operations was $1.5 million, compared to income of $1.0 million in Q3 2025; this loss included $4.1 million in non-recurring stock compensation and legal expenses.
- Nine-month 2026 loss from continuing operations was $0.4 million, compared to income of $2.2 million in the prior year period; this loss included $4.4 million in non-recurring stock compensation and legal expenses.
- Q3 2026 cash collections totaled $9.1 million, down from $10.0 million in the prior year quarter.
- Net cash provided by operating activities for the nine months ended September 30, 2026, was $1.351 million, compared to $3.693 million in the prior year period.
- Cash and cash equivalents were $2.929 million as of September 30, 2026, compared to $2.505 million as of December 31, 2025.
- The company maintains a debt-free balance sheet.
Guidance and Future Outlook:
- Management expects to scale operating leverage in line with volume growth without a corresponding increase in headcount to support continued margin expansion.
- The company does not expect the new pancreatic cancer program to contribute revenue in 2026 or 2027.
- Clinical validation and utility studies for the pancreatic cancer program are planned across 2026 and 2027, with reimbursement and launch activities to follow.
- Management indicated a steady cadence of operational improvement and disciplined execution for the remainder of 2026 and into 2027.
Business Segments and Product Lines:
- The company operates exclusively as a thyroid-only molecular diagnostics company following the discontinuation of its PancraGEN pancreatic testing business in May 2025.
- Q3 2026 thyroid test volume increased 7% year-over-year.
- Q3 2026 thyroid revenue increased 18% year-over-year.
- Trailing twelve-month thyroid revenue was $38.0 million, an increase of 13% on a comparable thyroid-only basis.
- Trailing twelve-month thyroid test volume growth was approximately 9%.
- Average thyroid revenue per test increased 11% in Q3 2026.
- Average turnaround time for ThyGeNEXT and ThyraMIR v2 improved approximately 11% in the first nine months of 2026 compared to the prior year.
- The company is developing a pancreatic cancer program using its existing next-generation sequencing and microRNA technology platforms, currently in analytical validation.
Market and Competitive Landscape:
- The company's combination approach of ThyGeNEXT (mutation detection) and ThyraMIR v2 (microRNA pathway insights) is positioned to provide physicians with confidence for patient-management decisions.
- The pancreatic cancer program design includes an extensive genomic panel and proprietary microRNA classification aligned with National Comprehensive Cancer Network (NCCN) guidelines.
Risks and Challenges:
- The pancreatic cancer program is not yet cleared or approved by the U.S. Food and Drug Administration, with no assurance that development will be completed on the anticipated timeline or at all.
- Forward-looking statements involve risks regarding the accuracy of revenue, cash flow, and net income estimates, as well as Pro Forma financial results.
- Risks include the company's prior history of operating losses, ability to finance the business, dependence on clinical services sales and reimbursements, and reliance on third parties for claims processing.
- Revenue recognition is based in part on estimates for future collections which may prove incorrect.
Management Commentary and Tone:
- CFO Chris McCarthy stated the company continued to convert revenue growth into margin expansion, reflecting operating leverage built into the business.
- McCarthy noted that gross margin expansion carried through to the bottom line, with Adjusted EBITDA margin improving to 20% from 14% in the prior year quarter.
- McCarthy highlighted that the debt-free balance sheet supports investment in laboratory automation, AI-enabled productivity, and R&D.
- CEO Tom Burnell described the third quarter as demonstrating the durability of the business built through the previous year's transition and the operating discipline carried forward.
- Management attributed results to steady execution across commercial and operations teams and the clinical value physicians see in their products.
Other Key Points:
- A one-for-five reverse stock split was effected on August 27, 2026; all share and per share numbers reflect this split.
- Reported year-over-year comparisons for the nine-month period are affected by the discontinuation of the PancraGEN business; Pro Forma results exclude PancraGEN for comparability.
- Beginning with the third quarter of 2026, reported year-over-year comparisons are presented on a directly comparable thyroid-only basis as the prior-year periods no longer include PancraGEN.
- The company incurred $4.1 million in non-recurring stock compensation costs and legal expenses in Q3 2026, which are excluded from Adjusted EBITDA.
- The company incurred $4.4 million in non-recurring stock compensation costs and legal expenses for the nine months ended September 30, 2026.
- Net cash used in investing activities for the nine months ended September 30, 2026, was $567,000.
- Net cash used in financing activities for the nine months ended September 30, 2026, was $360,000.
- Company
- INTERPACE BIOSCIENCES INC
- Sector
- Healthcare
- Industry
- Diagnostics & Research